Page last updated: 2024-10-15

hiv envelope protein gp41 (519-541)

Description

HIV envelope protein gp41 (519-541): the amino terminal peptide of HIV envelope protein gp41; lyses human erythrocytes and CD4+ lymphocytes [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID16132114
MeSH IDM0205599

Synonyms (7)

Synonym
hiv envelope protein gp41 (519-541)
128631-86-7
l-serinamide, l-alanyl-l-valylglycyl-l-isoleucylglycycl-l-alanyl-l-leucyl-l-phenylalanyl-l-leucylglycyl-l-phenylalanyl-l-leucylglycyl-l-alanyl-l-alanylglycyl-l-seryl-l-threonyl-l-methionylglycyl-l-alanyl-l-arginyl-
l-alanyl-l-valylglycyl-l-isoleucylglycyl-l-alanyl-l-leucyl-l-phenylalanyl-l-leucylglycyl-l-phenylalanyl-l-leucylglycyl-l-alanyl-l-alanylglycyl-seryl-l-threonyl-l-methionylglycyl-l-alanyl-l-arginyl-l-serinamide
fp-1, hiv
l-serinamide, l-alanyl-l-valylglycyl-l-isoleucylglycyl-l-alanyl-l-leucyl-l-phenylalanyl-l-leucylglycyl-l-phenylalanyl-l-leucylglycyl-l-alanyl-l-alanylglycyl-l-seryl-l-threonyl-l-methionylglycyl-l-alanyl-l-arginyl-
DTXSID90155952

Dosage Studied

ExcerptReference
" Dose-response curves indicated that their relative potency in inhibiting FP-I-induced hemolysis was approximately correlated with their previously reported anti-HIV activity."( Antivirals that target the amino-terminal domain of HIV type 1 glycoprotein 41.
Curtain, CC; Faull, K; Gordon, LM; Kirkpatrick, A; Leung, C; Mobley, PW; Waring, AJ, 1995
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's6 (85.71)18.2507
2000's1 (14.29)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]